Combining Gene Editing with Functional Analysis to Elucidate Disease Pathways

25 April 2017

At AACR 2017, Paul Diehl, Ph.D., Chief Operating Officer, Cellecta, discusses how the company makes use of new technologies such as gene editing and gene synthesis in combination with next-generation sequencing to develop assays enabling researchers to investigate how gene function and gene expression are linked to tumorigenesis. He describes two approaches – loss-of-function screens and targeted RNA expression analysis – that Cellecta has developed to help investigators better understand that relationship.